BCI Marketplace
Depression Neuromodulation trials

Neuromodulation and Attention Deficits in MDD

RecruitingNCT07111169Phase: NAStarted 2024-01-01

Summary

Multimodal study (Behavior, TMS, EEG) combining a sham-controlled intermittent theta burst stimulation (iTBS) intervention with an additional-singleton task and EEG to evaluate whether left dorsolateral prefrontal cortex (DLPFC) stimulation enhances cognitive control and modulates maladaptive attention processes in MDD and whether the effects are influenced by neuronavigated versus manual (Beam F3 method) localization of the stimulation site.

Eligibility

Sex
ALL
Min Age
18 Years
Max Age
55 Years

Inclusion Criteria: * 18-55 years * Right-handed * Normal or corrected normal visual acuity * MDD: meet the proposed DSM-5 MDD criteria, unmedicated or stable medicated within the last one month. Healthy subjects without any past or present psychiatric or neurological disorders. Exclusion Criteria

Locations

The Clinical Hospital of Chengdu Brain Science Institute, Chengdu Fourth People's Hospital, Jiujiang Branch (Chengdu Mental Health Center)
Chengdu, Sichuan, China

Interested in participating? View the full study details on ClinicalTrials.gov:

View on ClinicalTrials.gov →